Department of Pharmacology, University of North Carolina, Chapel Hill, USA.
National Institute of Standards and Technology, Gaithersburg, MD, USA.
Curr Opin Biotechnol. 2024 Aug;88:103176. doi: 10.1016/j.copbio.2024.103176. Epub 2024 Jul 29.
G protein-coupled receptors (GPCRs) are the largest family of transmembrane receptors in humans. Over 800 GPCRs regulate the (patho)biology of every organ, tissue, and cell type. Consequently, GPCRs are the most prominent therapeutic targets in medicine. Although over 30% of current U.S. Food and Drug Administration-approved drugs target GPCR signaling, most receptors remain understudied and therapeutically underutilized. Challenges include an incomplete understanding of GPCR signaling, pharmacology, structural biology, and the multiplicity of endogenous GPCR ligands, in addition to a scarcity of biological and pharmacological tools for elucidating GPCR-mediated cellular processes beyond initial signaling events. Various mammalian, insect, and yeast cell models currently address some of these needs. Here, we review recent advances in yeast synthetic biology that are helping to catalyze new and unexpected conceptual and technical breakthroughs in GPCR-based medicine and biotechnology.
G 蛋白偶联受体 (GPCRs) 是人类最大的跨膜受体家族。超过 800 种 GPCR 调节着每个器官、组织和细胞类型的 (病理) 生物学。因此,GPCR 是医学中最突出的治疗靶点。尽管超过 30%的美国食品和药物管理局批准的药物针对 GPCR 信号,但大多数受体仍未得到充分研究,治疗也未得到充分利用。挑战包括对 GPCR 信号、药理学、结构生物学的不完全了解,以及内源性 GPCR 配体的多样性,此外,用于阐明 GPCR 介导的细胞过程的生物学和药理学工具也很稀缺,而这些过程超出了初始信号事件。目前,各种哺乳动物、昆虫和酵母细胞模型都在满足这些需求。在这里,我们回顾了酵母合成生物学的最新进展,这些进展正在帮助推动基于 GPCR 的医学和生物技术的新概念和技术突破。